Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of ventilator-associated pneumonia due to Gram-negative bacteria

被引：1
|
作者：
Yusuf, Erlangga [1 ]
Zavascki, Alexandre P. [2 ]
Endeman, Henrik [3 ]
Kalil, Andre C. [4 ]
机构：
[1] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
[2] Univ Fed Rio Grande do Sul, Sch Med, Internal Med Dept, Porto Alegre, Brazil
[3] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands
[4] Univ Nebraska Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE USA
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2023年 / 29卷 / 11期
关键词：
COMBINATION THERAPY; AERUGINOSA; INFECTIONS;
D O I：
10.1016/j.cmi.2023.08.004
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：1364 / 1366
页数：3
相关论文
共 19 条
  • [1] Which trial do we need? Comparison of 7 versus 14 days of antibiotic therapy for ventilator-associated pneumonia due to highly resistant gram-negative bacteria
    Tleyjeh, Imad M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (09) : 1114 - 1116
  • [2] Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?
    Sarda, Cristina
    Fazal, Farhan
    Rello, Jordi
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (08) : 787 - 798
  • [3] Nebulized colistin for treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: we still need to straighten out the dose!
    Honore, Patrick M.
    Jacobs, Rita
    Hendrickx, Inne
    De Waele, Elisabeth
    De Regt, Jouke
    Spapen, Herbert D.
    CRITICAL CARE, 2015, 19
  • [4] Nebulized colistin for treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: we still need to straighten out the dose!
    Patrick M. Honore
    Rita Jacobs
    Inne Hendrickx
    Elisabeth De Waele
    Jouke De Regt
    Herbert D. Spapen
    Critical Care, 19
  • [5] Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study
    Michalopoulos, Argyris
    Fotakis, Dimitrios
    Virtzili, Simona
    Vletsas, Christodoulos
    Raftopoulou, Sylvia
    Mastora, Zefi
    Falagas, Matthew E.
    RESPIRATORY MEDICINE, 2008, 102 (03) : 407 - 412
  • [6] Treatment of ventilator-associated pneumonia (VAP) caused by highly resistant gram-negative bacteria with local instillation of colistin
    Marino, WD
    Hrachian, HH
    Chkrebtii, N
    Komorowski, AW
    Gunturu, SD
    Corpuz, MO
    CHEST, 2003, 124 (04) : 79S - 80S
  • [7] Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria
    Kidd, James M.
    Kuti, Joseph L.
    Nicolau, David P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 397 - 408
  • [8] Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective
    Giacobbe, Daniele Roberto
    Roberts, Jason A.
    Abdul-Aziz, Mohd H.
    de Montmollin, Etienne
    Timsit, Jean-Francois
    Bassetti, Matteo
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (07) : 963 - 979
  • [9] Efficacy of an intravenous colistin regimen in ventilator-associated pneumonia and bacteraemia due to multiresistant Gram-negative bacteria: preliminary results
    F Frantzeskaki
    A Tsimogianni
    M Balla
    A Betrosian
    Critical Care, 10 (Suppl 1):
  • [10] Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria
    Rattanaumpawan, Pinyo
    Lorsutthitham, Jintana
    Ungprasert, Puangpaka
    Angkasekwinai, Nasikarn
    Thamlikitkul, Visanu
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (12) : 2645 - 2649
12